PTC Therapeutics (PTCT) Moves 9.0% Higher: Will This Strength Last?
PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
PTC Therapeutics (PTCT) Receives a Buy from Morgan Stanley
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on PTC Therapeutics (PTCT – Research Report), with a price
Why PTC Therapeutics (PTCT) Stock Is Rallying Today
PTC Therapeutics (PTCT) is advancing 8% after investment bank Cantor Fitzgerald’ hiked its price target on the drug maker’s shares to $113 from $76. Cantor kept an Overweight rating on the name. Why Cantor Is So Bullish on PTCT The bank believes that,
PTC Therapeutics (NASDAQ:PTCT) Shares Up 6.1% Following Analyst Upgrade
Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) shot up 6.1% during trading on Monday after Cantor Fitzgerald raised their price target on the stock from $76.00 to $113.00. Cantor Fitzgerald currently has an overweight rating on the stock.
Cantor Fitzgerald lifts PTC Therapeutics stock target to $113
Cantor Fitzgerald's analysts demonstrated a positive outlook on PTC Therapeutics (NASDAQ:PTCT), increasing the price target to $113.00 from the previous $76.00. The firm maintains an Overweight rating on the stock.
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of “Hold” from Brokerages
PTC Therapeutics, Inc. (NASDAQ:PTCT – Get Free Report) has earned a consensus rating of “Hold” from the fifteen research firms that are covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation,
Cantor Fitzgerald Sticks to Its Buy Rating for PTC Therapeutics (PTCT)
Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) today and set a price target of
PTC Therapeutics' SWOT analysis: stock poised for growth amid regulatory challenges
PTC Therapeutics, Inc. (NASDAQ:PTCT), a biopharmaceutical company focused on developing and commercializing novel medicines for rare disorders, finds itself at a critical juncture. With a promising ...
Morgan Stanley Reaffirms Their Hold Rating on Amicus (FOLD)
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Hold rating on Amicus (FOLD – Research Report), with a price target ...